Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000-2009

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 4, 2015, Pages 406-412

  Van Altena, R ^a   De Vries, G ^b,c   Haar, C H ^a   De Lange, W C M ^a   Magis Escurra, C ^d   Van Den Hof, S ^b,e   Van Soolingen, D ^c,f   Boeree, M J ^d   Van Der Werf, T S ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Drug susceptibility testing; HIV; MDR TB; Outcome; Public health; Therapeutic drug monitoring

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; COTRIMOXAZOLE; CYCLOSERINE; DOXYCYCLINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ARTHRITIS; ARTICLE; CHILD; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEARING DISORDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LIVER DISEASE; LUNG LOBECTOMY; LUNG RESECTION; LUNG SURGERY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; NETHERLANDS; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PRURITUS; SPUTUM CULTURE; SPUTUM SMEAR; TENDON DISEASE; TREATMENT OUTCOME; VISUAL DISORDER; AGE DISTRIBUTION; COINFECTION; DRUG COMBINATION; DRUG EFFECTS; FOLLOW UP; HIV INFECTIONS; INFANT; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; NEWBORN; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR; SEX RATIO; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; NETHERLANDS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84925643716     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.14.0838     Document Type: Article

References (33)

1. World Health Organization: Global tuberculosis report 2014. WHO/HTM/TB/2014.08. Geneva, Switzerland: WHO, 2014.
2. Zumla A, Raviglione M, Hafner R, Reyn von C F. Tuberculosis. N Engl J Med 2013; 368: 745-755.
3. European Centre for Disease Prevention and Control/World Health Organization Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2014. Stockholm, Sweden: ECDC, 2014.
4. Ahuja S D, Ashkin D, Avendano M, et al. Multidrug-resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLOS MED 2012; 9: e1001300.
5. Liu C H, Li L, Chen Z, et al. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience. PLOS ONE 2011; 6: e19399.
6. Flament-Saillour M, Robert J, Jarlier V, Grosset J. Outcome of multi-drug-resistant tuberculosis in France: a nationwide casecontrol study. Am J Respir Crit Care Med 1999; 160: 587-593.
7. Granich R M, Oh P, Lewis B, Porco T C, Flood J. Multidrug resistance among persons with tuberculosis in California, 1994-2003. JAMA 2005; 293: 2732-2739.
8. Minion J, Gallant V, Wolfe J, Jamieson F, Long R. Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: demographic and disease characteristics. PLOS ONE 2013; 8: e53466.
9. Anderson L, Tamne S, Watson J, et al. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Euro Surveill 2013; 18: 20601.
10. Alffenaar J-W C, Kosterink J G W, van Altena R, van der Werf T S, Uges D R A, Proost J H. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit 2010; 32: 97-101.
11. Pranger A D, van Altena R, Aarnoutse R E, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011; 38: 888-894.
12. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva, Switzerland: WHO, 2006.
13. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
14. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. WHO/HTM/TB/2011.6. Geneva, Switzerland: WHO, 2011.
15. Migliori G B, Zellweger J P, Abubakar I, et al. European Union standards for tuberculosis care. Eur Respir J 2012; 39: 807-819.
16. Geerligs WA, van Altena R, De Lange W C M, van Soolingen D, van der Werf T S. Multidrug-resistant tuberculosis: longterm treatment outcome in the Netherlands. Int J Tuberc Lung Dis 2000; 4: 758-764.
17. Bastos ML, Hussain H, Weyer K, et al. Treatment outcomes of patients with multidrug- and extensive drug-resistant tuberculosis according to drug susceptibility testing to firstand second-line drugs: an individual patient data meta-analysis. Clin Infect Dis 2014; 59: 1364-1374.
18. Falzon D, Jaramillo E, Schünemann H J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
19. Van Deun A, Maug A K J, Salim M A H, et al. Short, highly effective, and inexpensive standardized treatment of multidrugresistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
20. Piubello A, Harouna SH, Souleymane MB, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18: 1188-1194.
21. Sotgiu G, Centis R, D'Ambrosio L, Spanevello A, Migliori G B, International Group for the study of linezolid. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J 2013; 42: 288-290.
22. Cholo M C, Steel H C, Fourie P B, Germishuizen W A, Anderson R. Clofazimine: current status and future prospects. J Antimicrob Chemother 2012; 67: 290-298.
23. Dey T, Brigden G, Cox H, Shubber Z, Cooke G, Ford N. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013; 68: 284-293.
24. Xu J, Lu Y, Fu L, et al. In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters. Int J Tuberc Lung Dis 2012; 16: 1119-1125.
25. Grosset J H, Tyagi S, Almeida D V, et al. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med 2013; 188: 608-612.
26. Marrone M T, Venkataramanan V, Goodman M, Hill A C, Jereb J A, Mase S R. Surgical interventions for drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2013; 17: 6-16.
27. Zumla A, Hafner R, Lienhardt C, Hoelscher M, Nunn A. Advancing the development of tuberculosis therapy. Nat Rev Drug Discov 2012; 11: 171-172.
28. Lienhardt C, Raviglione M, Spigelman M, et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 2012; 205 (Suppl 2): S241-S249.
29. Diacon A H, Pym A, Grobusch M P, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
30. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrugresistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
31. Alffenaar J W C, van der Laan T, Simons S, et al. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480. Antimicrob Agents Chemother 2011; 55: 1287-1289.
32. Reddy V M, Dubuisson T, Einck L, et al. SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro. J Antimicrob Chemother 2012; 67: 1163-1166.
33. Diacon A H, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380: 986-993.